Srikumar Sahasranaman

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

Thomas J. Kipps, Herbert Eradat, Sebastian Grosicki et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2015 · 186 citations · Full text

Arm B, Tumor Biology, Biologic Activity +13

The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys

Laurent Grégoire, Nicolas Morin, Bazoumana Ouattara et al. · Parkinsonism & Related Disorders · 2011 · 107 citations

Neurophysiology, Medicine, Neurotransmitter +10

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

Jeffrey R. Infante, Antoine Hollebecque, Sophie Postel‐Vinay et al. · Clinical Cancer Research · 2016 · 70 citations

Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma

Kevin Mortimer, Tim Harrison, Yufei Tang et al. · British Journal of Clinical Pharmacology · 2006 · 51 citations · Full text

Model-Based Covariate Pharmacokinetic Analysis and Lack of Cortisol Suppression by the New Inhaled Corticosteroid Ciclesonide Using a Novel Cortisol Release Model

Shashank Rohatagi, Sriram Krishnaswami, Marc Pfister et al. · American Journal of Therapeutics · 2005 · 45 citations